Edwards Lifesciences (EW) Non-Current Debt (2009 - 2026)

Edwards Lifesciences has reported Non-Current Debt for 18 years, with the latest figure at $598.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed 0.12% year-over-year to $598.5 million; the trailing twelve-month figure through Mar 2026 stood at $598.5 million (changed 0.12% YoY), and the FY2025 full-year result was $598.3 million, changed 0.1% from the prior year.
• Non-Current Debt for Q1 2026 stood at $598.5 million, roughly flat from $598.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $598.5 million in Q1 2026, with the low at $595.9 million in Q1 2022.
• Average Non-Current Debt over 5 years is $597.2 million, with a median of $597.2 million recorded in 2024.
• Year-over-year, Non-Current Debt advanced 0.12% in 2022 and advanced 0.1% in 2025.
• Tracing EW's Non-Current Debt over 5 years: stood at $596.3 million in 2022, then rose by 0.12% to $597.0 million in 2023, then increased by 0.12% to $597.7 million in 2024, then rose by 0.1% to $598.3 million in 2025, then advanced by 0.03% to $598.5 million in 2026.
• The last three Non-Current Debt figures came in at $598.5 million (Q1 2026), $598.3 million (Q4 2025), and $598.2 million (Q3 2025), per Business Quant data.

Peer Comparison